New Breast Cancer Pill Triggered by a Blood Test: Who Qualifies?
If you're on a first-line aromatase inhibitor plus a CDK4/6 inhibitor for HR-positive, HER2-negative metastatic breast cancer, there's a new option worth understanding. On September 4, 2026, the FDA approved camizestrant (Etcamah) as the first cancer therapy triggered by a blood test rather than a growing tumor on a scan. In the trial that won it approval, switching the moment an ESR1 mutation appeared in the blood roughly doubled the time before the cancer advanced. Whether it also extends life is what the next few years of follow-up will answer.
The change here is subtler than a new drug, and larger. Camizestrant is a next-generation oral estrogen receptor degrader, and its activity in ESR1-mutant disease was already established. What's new is when you take it. For the first time, an oncology drug label makes a blood test, not imaging, the trigger for switching treatment. A Guardant360 CDx draw every three months can now change your regimen while your scans still look stable.
What the switch actually bought
SERENA-6 was a 315-patient phase 3 trial with a very specific setup. Adults on first-line aromatase inhibitor plus a CDK4/6 inhibitor were screened every two to three months with Guardant360. Of 3,256 people screened, 548 developed an ESR1 mutation before any change on their scans, and 315 were randomized to swap the aromatase inhibitor for camizestrant 75 mg daily or stay the course. Both arms kept the CDK4/6 inhibitor.
The switch nearly doubled median progression-free survival: 16.8 months versus 9.2. It also delayed a second progression on the next line of therapy, 25.7 versus 19.1 months, and quality of life held up longer. That's the largest progression-free gain any oral drug in this class has posted in this setting.
The window a scan can't see
ESR1 mutations aren't rare here. On a first-line aromatase inhibitor, roughly a third to over half of tumors develop one at progression, and it's the dominant reason first-line hormonal treatment stops working. The mutant estrogen receptor drives signaling without needing any estrogen, so lowering estrogen no longer helps.
Serial ctDNA testing picks that up months before a scan sees the cancer grow. In prospective monitoring cohorts, the lead time averaged around 6.7 months. That's the window the new indication opens. In the old model, you learned about resistance when imaging showed growth. Now the blood flags it earlier, and the label lets you act.
How camizestrant sits among earlier SERDs
Camizestrant isn't the first oral estrogen receptor degrader to reach a phase 3 readout, and several have failed. What sets this approval apart is the trigger, not the molecule.
| Drug (trial) | When it starts | PFS extension |
|---|---|---|
| Camizestrant (SERENA-6) | ctDNA-triggered switch, 1st line | 16.8 vs 9.2 months |
| Fulvestrant (PADA-1) | ctDNA-triggered switch, 1st line | 11.9 vs 5.7 months |
| Elacestrant (EMERALD) | After scan progression, ESR1+ | 8.6 vs 1.9 months* |
| Fulvestrant | After scan progression, post-AI | about 2 months |
*In patients with prior endocrine therapy plus a CDK4/6 inhibitor for at least 12 months. Two patterns matter. Doubling progression-free survival with a ctDNA-triggered switch isn't unique to camizestrant. Fulvestrant, the injectable first-generation drug in this class, did essentially the same thing in PADA-1 four years earlier. And once the switch happens later, after scans confirm growth, the ESR1-directed benefit shrinks. That's the case for acting inside the early window rather than waiting for it to close.
What overall survival hasn't shown yet
The FDA's own oncology advisors weren't convinced this window matters for how long people live. In April 2026, the Oncologic Drugs Advisory Committee voted 6 to 3 against approval, citing immature overall survival data and no direct evidence that a molecular-triggered switch beats a switch at radiographic progression. The FDA granted accelerated approval anyway.
The objection is fair. Second progression-free survival did improve on camizestrant, a signal the delay isn't just borrowed time, and PADA-1 ran the same play years earlier and also hasn't shown a survival benefit yet. Both trials are still following patients. Until those readouts land, longer overall survival isn't on the label.
The safety profile is a commitment too. Camizestrant's label carries a boxed warning for QTc prolongation, particularly with other QTc-prolonging drugs, plus warnings for bradycardia and embryo-fetal harm. Brief visual disturbances such as photopsia have been reported in the SERENA trials and were generally short-lived.
Who this is for
The indication is narrow. It applies if you have HR-positive, HER2-negative metastatic disease and are on a first-line aromatase inhibitor with a CDK4/6 inhibitor. Ask your oncologist whether Guardant360 CDx should be part of your surveillance every three months. If an ESR1 mutation appears before your imaging progresses, the option is to swap the aromatase inhibitor for camizestrant 75 mg daily and keep the CDK4/6 inhibitor.
Two situations sit outside this. If you're ESR1 wild-type, the trial didn't show a benefit. If you've already progressed on imaging, SERENA-6 doesn't apply; elacestrant and other endocrine options are the tested moves there.
One caveat about the test. A negative Guardant360 result doesn't fully rule out an ESR1 mutation, especially in low-shedding or bone-only disease. That's a reason to keep the every-three-months cadence rather than test once, and to consider a tissue biopsy at real progression if the blood keeps coming back clean.
For the first time in oncology, a blood test rather than a growing tumor is what changes treatment. In the right patient, the switch buys about seven extra months before the disease advances. Whether it also extends life is what the next few years of follow-up will settle.